Ohio State University

About: Ohio State University is a education organization based out in Columbus, Ohio, United States. It is known for research contribution in the topics: Population & Cancer. The organization has 102421 authors who have published 222715 publications receiving 8373403 citations. The organization is also known as: Ohio State & The Ohio State University.

MMSPEED: multipath Multi-SPEED protocol for QoS guarantee of reliability and. Timeliness in wireless sensor networks

Abstract: In this paper, we present a novel packet delivery mechanism called Multi-Path and Multi-SPEED Routing Protocol (MMSPEED) for probabilistic QoS guarantee in wireless sensor networks. The QoS provisioning is performed in two quality domains, namely, timeliness and reliability. Multiple QoS levels are provided in the timeliness domain by guaranteeing multiple packet delivery speed options. In the reliability domain, various reliability requirements are supported by probabilistic multipath forwarding. These mechanisms for QoS provisioning are realized in a localized way without global network information by employing localized geographic packet forwarding augmented with dynamic compensation, which compensates for local decision inaccuracies as a packet travels towards its destination. This way, MMSPEED can guarantee end-to-end requirements in a localized way, which is desirable for scalability and adaptability to large scale dynamic sensor networks. Simulation results show that MMSPEED provides QoS differentiation in both reliability and timeliness domains and, as a result, significantly improves the effective capacity of a sensor network in terms of number of flows that meet both reliability and timeliness requirements up to 50 percent (12 flows versus 18 flows).

Implicit Attitude Measures: Consistency, Stability, and Convergent Validity

Abstract: In recent years, several techniques have been developed to measure implicit social cognition. Despite their increased use, little attention has been devoted to their reliability and validity. This article undertakes a direct assessment of the interitem consistency, stability, and convergent validity of some implicit attitude measures. Attitudes toward blacks and whites were measured on four separate occasions, each 2 weeks apart, using three relatively implicit measures (response-window evaluative priming, the Implicit Association Test, and the response-window Implicit Association Test) and one explicit measure (Modern Racism Scale). After correcting for interitem inconsistency with latent variable analyses, we found that (a) stability indices improved and (b) implicit measures were substantially correlated with each other, forming a single latent factor. The psychometric properties of response-latency implicit measures have greater integrity than recently suggested.

Toward a Psychology of Framing Effects

Abstract: Framing is the process by which a communication source constructs and defines a social or political issue for its audience. While many observers of political communication and the mass media have discussed framing, few have explicitly described how framing affects public opinion. In this paper we offer a theory of framing effects, with a specific focus on the psychological mechanisms by which framing influences political attitudes. We discuss important conceptual differences between framing and traditional theories of persuasion that focus on belief change. We outline a set of hypotheses about the interaction between framing and audience sophistication, and test these in an experiment. The results support our argument that framing is not merely persuasion, as it is traditionally conceived. We close by reflecting on the various routes by which political communications can influence attitudes.

Extremely Disadvantaged Neighborhoods and Urban Crime

Abstract: Drawing on Wilson (1987), this article assesses two hypotheses concerning the relationship between neighborhood disadvantage and crime : (1) extremely disadvantaged neighborhoods have unusually high rates of crime; and (2) local structural disadvantage is equally important in influencing crime in black and white neighborhoods. Hence, racial differences in structural disadvantage account for black-white differences in crime across communities. To test these hypotheses, the authors examine 1990 census and crime data for local areas in the city of Columbus, Ohio. The analysis lends substantial support for both arguments, particularly for the influence of structural disadvantage on violent crime

Five Versus More Than Five Years of Tamoxifen Therapy for Breast Cancer Patients With Negative Lymph Nodes and Estrogen Receptor-Positive Tumors

Abstract: BACKGROUND In 1982, the National Surgical Adjuvant Breast and Bowel Project initiated a randomized, double-blinded, placebo-controlled trial (B-14) to determine the effectiveness of adjuvant tamoxifen therapy in patients with primary operable breast cancer who had estrogen receptor-positive tumors and no axillary lymph node involvement. The findings indicated that tamoxifen therapy provided substantial benefit to patients with early stage disease. However, questions arose about how long the observed benefit would persist, about the duration of therapy necessary to maintain maximum benefit, and about the nature and severity of adverse effects from prolonged treatment. PURPOSE We evaluated the outcome of patients in the B-14 trial through 10 years of follow-up. In addition, the effects of 5 years versus more than 5 years of tamoxifen therapy were compared. METHODS In the trial, patients were initially assigned to receive either tamoxifen at 20 mg/day (n = 1404) or placebo (n = 1414). Tamoxifen-treated patients who remained disease free after 5 years of therapy were then reassigned to receive either another 5 years of tamoxifen (n = 322) or 5 years of placebo (n = 321). After the study began, another group of patients who met the same protocol eligibility requirements as the randomly assigned patients were registered to receive tamoxifen (n = 1211). Registered patients who were disease free after 5 years of treatment were also randomly assigned to another 5 years of tamoxifen (n = 261) or to 5 years of placebo (n = 249). To compare 5 years with more than 5 years of tamoxifen therapy, data relating to all patients reassigned to an additional 5 years of the drug were combined. Patients who were not reassigned to either tamoxifen or placebo continued to be followed in the study. Survival, disease-free survival, and distant disease-free survival (relating to failure at distant sites) were estimated by use of the Kaplan-Meier method; differences between the treatment groups were assessed by use of the logrank test. The relative risks of failure (with 95% confidence intervals [CIs]) were determined by use of the Cox proportional hazards model. Reported P values are two-sided. RESULTS Through 10 years of follow-up, a significant advantage in disease-free survival (69% versus 57%, P < .0001; relative risk = 0.66; 95% CI = 0.58-0.74), distant disease-free survival (76% versus 67%, P < .0001; relative risk = 0.70; 95% CI = 0.61-0.81), and survival (80% versus 76%, P = .02; relative risk = 0.84; 95% CI = 0.71-0.99) was found for patients in the group first assigned to receive tamoxifen. The survival benefit extended to those 49 years of age or younger and to those 50 years of age or older. Tamoxifen therapy was associated with a 37% reduction in the incidence of contralateral (opposite) breast cancer (P = .007). Through 4 years after the reassignment of tamoxifen-treated patients to either continued-therapy or placebo groups, advantages in disease-free survival (92% versus 86%, P = .003) and distant disease-free survival (96% versus 90%, P = .01) were found for those who discontinued tamoxifen treatment. Survival was 96% for those who discontinued tamoxifen compared with 94% for those who continued tamoxifen treatment (P = .08). A higher incidence of thromboembolic events was seen in tamoxifen-treated patients (through 5 years, 1.7% versus 0.4%). Except for endometrial cancer, the incidence of second cancers was not increased with tamoxifen therapy. CONCLUSIONS AND IMPLICATIONS The benefit from 5 years of tamoxifen therapy persists through 10 years of follow-up. No additional advantage is obtained from continuing tamoxifen therapy for more than 5 years.